Veno-occlusive disease (VOD) is one of the most serious complications following hematopoietic stem cell transplantation (HSCT) and is associated with a high mortality. We conducted a large trial on the clinical significance of protein C (PC) and procollagen III peptide (PNPIII) levels, which have been described as possible diagnostic markers of VOD. In total, 350 patients undergoing allogeneic HSCT were included. PC and PNPIII levels were analyzed prior to conditioning and weekly until 8 weeks after the HSCT. Signs of VOD and other transplantation-related complications (graft-versushost disease (GVHD), toxicity, microangiopathic hemolytic anemia, infection) were recorded weekly throughout the trial. Patients showed a significant drop of the PC levels in VOD (70.3 vs 96.3%, Po0.001) and with increasing severity of aGVHD. Steroids increased the PC levels (69.4% vs 109.4%, Po0.001). The highest PNPIII levels were registered in patients with VOD (mean 6.3 IU/ ml). Patients with aGVHD showed an elevation of PNPIII, especially patients with hepatic aGVHD. PC levels during conditioning do not predict VOD (98.5 vs 76.5%, NS). Although PC and PNPIII may play a role in the pathogenesis of VOD they cannot discriminate between complications with jaundice and are only of limited help in the differential diagnosis of VOD. Bone Marrow Transplantation (2005) 36, 631-637.
Veno-occlusive disease (VOD) is one of the most serious complications following hematopoietic stem cell transplantation (HSCT) and is associated with a high mortality. We conducted a large trial on the clinical significance of protein C (PC) and procollagen III peptide (PNPIII) levels, which have been described as possible diagnostic markers of VOD. In total, 350 patients undergoing allogeneic HSCT were included. PC and PNPIII levels were analyzed prior to conditioning and weekly until 8 weeks after the HSCT. Signs of VOD and other transplantation-related complications (graft-versushost disease (GVHD), toxicity, microangiopathic hemolytic anemia, infection) were recorded weekly throughout the trial. Patients showed a significant drop of the PC levels in VOD (70.3 vs 96.3%, Po0.001) and with increasing severity of aGVHD. Steroids increased the PC levels (69.4% vs 109.4%, Po0.001). The highest PNPIII levels were registered in patients with VOD (mean 6.3 IU/ ml). Patients with aGVHD showed an elevation of PNPIII, especially patients with hepatic aGVHD. PC levels during conditioning do not predict VOD (98.5 vs 76.5%, NS). Although PC and PNPIII may play a role in the pathogenesis of VOD they cannot discriminate between complications with jaundice and are only of limited help in the differential diagnosis of VOD. VOD is believed to be caused by toxic injury of the sinusoidal endothelial cells and hepatocytes with subsequent damage of central veins in zone 3 of the hepatic acinus. 4 The endothelial cell damage may lead to exposure of tissue factor and deficiencies in the natural anticoagulants. 5 Changes in plasma PC levels are mostly related to redistibution into edema and ascites fluid. The serum aminopropeptide of type III procollagen (PNPIII) may be a sign of enhanced hepatic collagen formation. 6 The onset of VOD is usually observed within 1 month after the HSCT. In this period conditioning effects, infection, acute graft-versus-host disease (aGVHD), or microangiopathic hemolytic anemia (MAHA) may mimic the syndrome. Nevertheless prompt detection of VOD, often based on clinical criteria, 3 is essential, since early antithrombotic therapy represents the only promising tool so far. 7 Numerous serum and plasma proteins have been reported to be abnormal in patients with VOD, including endothelial cell markers and coagulation proteins. The plasma PC (protein C) 8 and the serum PNPIII 9, 6 have been reported as predictive laboratory parameters for the diagnosis of VOD. As there is considerable controversy about the clinical significance of PC and PNPIII we conducted a large trial in allogeneic stem cell recipients to validate the diagnostic relevance of these parameters allowing discrimination between this syndrome and other forms of liver injury following HSCT.
Patients and methods

Study population
Between January 1998 and October 2001, 350 patients 12 years of age and older receiving allogeneic hematopoietic stem cell grafts were included in this prospective analysis. Patients were admitted for a variety of hematological disorders at various stages of their disease. A total of 3471 weeks were documented with a median observation period of 8 weeks (range 2-151). The baseline demographic of the patients and the transplant characteristics are summarized in Table 1 .
Signed informed consent was obtained from all patients or their legal representatives allowing analysis of all clinical and laboratory data mentioned in this paper.
Trial design and procedures
This was a single-center (Jose´-Carreras Transplantation Unit, University of Munich, Germany), prospective study evaluating the specifity and sensitivity of PC plasma levels and PNPIII serum levels in patients with VOD and other TRC with jaundice following HSCT. No exclusion criteria were defined.
Transplantation course
Once a week at the timepoint of PC and PNPIII measurements the clinical situation was documented.
Uncomplicated HSCT was defined as the absence of organ dysfunction (defined as bilirubin 42.0 mg/dl, creatinine 41.5 mg/dl, PaCO 2 o32 mmHg, PaCO 2 450 mmHg, systolic blood pressure o90 mmHg), no appearance of TRC (defined as: GVHD (grade 4I), VOD, MAHA, infection, regimen related toxicity), and no need of plasma exchange (defined as plasmapheresis with application of fresh frozen plasma, dialysis, and hemofiltration).
Graft-versus-host disease prophylaxis was given as shown in Table 1 . Acute graft-versus-host disease (aGVHD) was graded by clinical and biochemical criteria 10 and confirmed by biopsy in a minority of patients. GVHD patients with aGVHD (4grade I) received first line standard therapy with prednisolone (maximum 3 mg/kg/day). Corticosteroid treatment was reduced (10% of dosage every 3 days) as soon as GVHD was controlled. Chronic graft-versus-host disease (cGVHD) was graded by clinicopathological aspects.
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Hepatic VOD was diagnosed and classified by the clinical syndrome of liver enlargement and pain, fluid retention and weight gain, and elevated serum bilurubin concentration 42 mg/dl. 2 The diagnosis was confirmed by ultrasound, Doppler ultrasound, and transjugular liver biopsy in all cases. Patient characteristics are given in Table 1 .
MAHA was defined as the simultaneous occurrence of intravascular hemolysis characterized by the appearance of 45% schistocytes in peripheral blood smears, de novo thrombocytopenia, and elevation of LDH levels. 12, 13 Only moderate or severe cases of MAHA requiring therapeutic intervention (application of fresh frozen plasma or therapeutic plasmapheresis) were registered.
Infectious complications were defined by clinical and laboratory parameters (fever: 438.51C irrespective of underlying microorganisms; sepsis: fever plus organ dysfunction as indicated by disseminated intravascular coagulation (DIC), positive lactate, new renal insufficiency, or PCO 2 o32 mmHg, no need of vasopressors; septic shock: sepsis and need of vasopressors).
Blood sampling and assessments
Prior to conditioning and once a week blood samples were obtained on the morning via the central vein catheter.
Citrated blood samples (4.3 ml Primavette S s coagulation tubes, Kabe Labortechnik, Nuembrecht-Elsenroth, Germany; 3.8% sodium citrate 9:1) were centrifuged after collection (3.000 g at room temperature for 15 minutes) for complete platelet removal. Serum tubes (10 ml; Kabe Labortechnik, Nuembrecht-Elsenroth, Germany) were used for analyses of serum parameters. EDTA tubes 2 for 4 days) combined with total body irradiation (2-4 Gy for 1 day, dose rate 4.5 cGy/min), and intravenous cyclophosphamide (40 mg/kg for 2-3 days); conventional chemotherapy ¼ Second stem cell infusion (same donor) after conventional chemotherapy because of relapse or engraftment rejection (cytarabine; fludarabine-amsacrinecytarabine; melphalane; ifosfamide-cyclophosphamide-etoposide; fludarabinecytarabine-idarubicine; cytarabine-amsacrine; BCNU-etoposide-cytarabinemelphalane; cyclophosphamide-vincristine-bleomycin); antithymocyte globulin ¼ intravenous ATG (10-30 mg/kg for 3-5 days); CyA ¼ continuous infusion of cyclosporine from day À1 until day 28 (10mg/kg CyA on day À1; 5 mg/kg CyA from day 0 until day 4; 3 mg/kg CyA from day 5 until day 28) followed by orally administered cyclosporine from day 28 (2 mg/kg CyA; plasma levels 150 to 200 ng/ml in the first 3 months after HSCT with gradual tapering); MTX ¼ intravenous methotrexate (15 mg/m 2 on day 1, 10 mg/m 2 on day 3 and 6); MMF ¼ intravenous mycophenolate mofetil (4 Â 500 mg from day 0).
(4 ml; Kabe Labortechnik, Nuembrecht-Elsenroth, Germany) were obtained for routine blood count.
All samples were processed locally (Institute of Clinical Chemistry, University of Munich, Germany). Daily validation of the interassay precision showed a standard deviation of less than 5% throughout the study period given by the manufacturer. Platelet count (normal range: 150-440 Â 10 9 /l) was analyzed using a H6000 analyser (Coulter, USA). Liver function was detected by total bilirubin (DPD Method, Roche, normal range: o1.0 mg/dl).
PC plasma activity (Chromogenic test; Berichrom PC Dade Behring; Germany; normal range: 70-140%) and procollagen III peptide serum levels (Prokollagen III-Peptid RIA; Schering; Germany; normal range: 0.3-0.8 U/ml) were determined by commercial tests. Aliquots were frozen and stored at À701C until assayed.
Concomitant medication
Concomitant medication, plasma exchange and transfused blood products (erythrocytes, platelets, fresh frozen plasma) were noted weekly. All patients received intravenous heparin (100 IE/h) prophylactically during the whole transplantation period and full parenteral nutrition from day À1 until engraftment. Nutrients contained all lipophilic and hydrophilic vitamins and trace elements. Gut decontamination was performed using oral nystatine, colistin, and amphotericin B. Herpes simplex virus prophylaxis was conducted by intraveneous adminstration of aciclovir (10 mg/kg BW t.i.d.). Antibiotic and antimycotic prophylaxis was given as indicated.
Statistical analysis
Based on the Jones criteria and on recent retrospective data 14 with the assumption that the expected proportion of patients with VOD recruited to the study was 4%, a sample size of at least 300 patients was planned to achieve a number of at least 10 VOD patients. Data are given as percentages or as means and 95% confidence intervals for continuous variables if not otherwise indicated. Categorial and ordinal variables were given as median and range. Differences among the groups were analyzed by the MannWhitney U test for ordinal data, and by Pearson's w 2 test for categorial variables. Continuous variables were compared with the Student t test if they followed a normal distribution or with the Wilcoxon rank test if they followed a skewed distribution. All statistical tests were two-tailed, P-values below 0.05 being regarded as significant. Statistical analyses were performed with the Statistical Package for the Social Sciences (SPSS for Windows 10.0, SPSS Inc., Chicago, IL, USA).
Results
Uncomplicated HSCT
There was no difference between full intensity conditioning (FIC) regimens (see Table 1 ) and reduced intensity conditioning (RIC) regimens (see Table 1 ) regarding the PC and PNPIII serum levels, and the routine laboratory parameters.
Protein C: During the conditioning phase PC plasma levels temporarily dropped (see Figure 1b) . Subanalysis reveals that total body irradiation (TBI) had no impact on the PC plasma levels (data not shown). Also conditioning regimens with or without busulfan did not impair the PC plasma levels (busulfan: 97.8 vs 98.5%, NS; non busulfan: 98.3 vs 98.5%, NS). However, ATG lowered the PC levels significantly (86 vs 98%; Po0.05), independently from the previous conditioning regimen.
During the further course of uncomplicated transplantation the lowest PC plasma levels within the normal range were achieved during aplasia. After engraftment PC levels recovered (see Figure 1b) .
Procollagen III peptide: Serum levels of PNPIII were elevated before HSCT, increased continually and reached the highest levels 4 weeks after the HSCT (see Figure 1a) . The different conditioning regimens, the ATG prophylaxis, and TBI did not impact on the PNPIII levels (data not shown).
Transplant related complications
The incidence of the different TRC is shown in Table 2 . Patients, who had TRC had lower PC levels until week 2 after HSCT and showed higher PC levels in week 3 and 4 compared to patients with uncomplicated HSCT (data not shown). Patients with ATG prophylaxis had significantly more TRC (infection, GVHD, MAHA, VOD) compared to patients without ATG prophylaxis (71.2 vs 65.2%, P ¼ 0.008). The PNPIII serum levels in patients with VOD and aGVHD are presented in Figure 2a and b.
Veno-occlusive disease: Patients with VOD had an median onset of this TRC at day 28 (1-124). Patients with VOD showed significant lower PC levels compared to patients without any TRC (70.3 vs 96.3%, Po0.001). The PC plasma levels before stem cell transfusion did not differ in patients who developed later VOD from those patients who had no later VOD (week À2: 98.5 vs 76.5, NS; week À1: 83.4 vs 82.6%, NS; week 0: 89.4 vs 79.9%, NS). The highest PNPIII levels are registered in patients with VOD compared to patients with other complications (data not shown). In patients with PNPIII serum levels above 2.2 IU/ml the sensitivity for VOD was 100%, the specifity for VOD 8.5%.
Infection, MAHA, and aGVHD: The PC levels decreased inversely proportionally to the severity of infection (data not shown). Patients with MAHA had lowered PC plasma levels within the normal range compared to patients without any TRC (68.6 vs 96.3%, Po0.001).
Patients showed a significant drop of the PC levels with increasing severity of aGVHD independent from the organ manifestation before application of steroids (data not shown). Starting steroids because of aGVHD increased the PC plasma levels significantly (68 vs 108%; Po0.05).
The PNPIII levels strongly correlated to the severity of infection independent from the leukocyte count (see Figure 3a ). An aGVHD led to an elevation of PNPIII levels depending on the grade of the hepatic aGVHD, independently from the use of steroids (see Figure 3b ). Numbers give cases (percentage).
Protein C and PNPIII in stem cell transplantation M Pihusch et al PNPIII serum levels showed a wide overlap in all transplant-related complications with jaundice (see Figure 3c ).
Discussion
The clinical diagnosis of VOD is difficult and based on the clinical triad of hepatomegaly, weight gain, and jaundice. 2, 3 However, many causes of jaundice and liver dysfunction such as GVHD, MAHA, toxic effects, or infection can mimic the symptoms. Nevertheless, prediction of VOD in high-risk patients would be helpful, since early and correct therapeutic decisions are crucial. 7 Confirmation of the diagnosis by liver biopsy is cumbersome and poses a significant risk of bleeding in the thrombocytopenic patient, apart from possible falsely negative results. Ultrasound findings are not sufficiently sensitive in the early phase. 15 Also, the transvenous wedged hepatic venous pressure measurements are highly specific but only moderately sensitive for VOD. 16 Numerous plasma and serum proteins have been reported to be abnormal in VOD patients including coagulation proteins and procollagen peptides. 17 In many retrospective analyses the natural anticoagulant PC, 8, 5 synthesized and released by hepatocytes, and the serum aminopropeptide of type III procollagen, accumulating in enhanced collagen formation, were analyzed to figure out whether they were useful markers of hepatic VOD after HSCT. 9, 18 Results were controversial though. While some authors found PC to be a useful marker to predict VOD 19 or confirm its diagnosis, 20, 5 other studies stated that this hemostatic parameter is not helpful to identify VOD patients. 17 PNP III was also shown to predict and diagnose VOD after HSCT by some authors 21, 6, 22 while others did not find significant changes of the propeptide of type III procollagen. 17 On the other hand, there are data from animal models showing an initiation of sinusoidal obstructive syndrome by changes in sinusoidal endothelial cells followed by embolisation of the siudoid by sinusoidal lining cells. Alterations of hemostatic parameters are suggested to be an epiphenomenon in this case. 23 As there is considerable controversy about the diagnostic utility of these markers we conducted a large prospective trial to validate the sensitvity and specifity of PC and PNPIII levels in the diagnosis of VOD following HSCT. Our study shows that low PC levels during conditioning do not predict VOD. Prophylaxis with ATG decreased the PC levels. The PNPIII levels continually increased during the post tansplantation course. The highest PNPIII serum Activated PC plays a pivotal role in the inhibition of monocytes and macrophages 24 with consecutive inhibition of inflammatory mediators and of the coagulation cascade. We could not prove a predictive value of this natural anticoagulant for occurrence of VOD. In our large trial we observed low PC levels during conditioning. However, this is rather due to the ATG-induced DIC, reflected by increasing D-dimer levels, low platelets, and consumption of antithrombin. 25 A further drop in the PC levels was registered during the first week after HSCT. As PC is mainly synthesized by hepatocytes, this might be indicative for an impaired liver function after conditioning or for disappearance into ascites or edema fluid, which is seen in other TRC different from VOD, and is thus not predictive for later VOD.
Our data indicate increasing PNPIII levels during HSCT. Elevated PNPIII serum levels are described in a multitude of disorders accompanied by relevant liver fibrosis, 26 as seen in liver biopsies of VOD patients. Fibrous alterations in the hepatic sinusoids occur during the development of VOD. These changes are accompanied by the deposition of type III collagen in the liver tissue. 6 VOD patients and patients with severe hepatic aGVHD had the highest levels of PNP III in our trial. Both TRC are accompanied with significant fibrous alterations and hepatic remodelling processes. In some smaller trials serum concentrates of PIIINP seemed to be of value as an early marker for VOD 6, 18 while in some other studies they did not. 17 PNPIII, a precursor peptide of type III collagen, accumulates in enhanced collagen formation as possible in VOD and severe GVHD of the liver.
A broad overlap of the PNPIII levels was seen in all TRC with hyperbilirubinemia. PNPIII is therefore only of very limited help for the differential diagnosis of VOD. However, the small sample size of 15 patients with VOD and the heterogeneity of the studied population in terms of underlying disease, conditioning regimens, or additional medication might be responsable for the lack of significance in this context. Increasing bilirubin levels during HSCT, caused by toxic drugs, might be one reason for the elevation of PNPIII levels, as PNPIII is cleaved by the liver. 27 In addition, a tubular damage 28 by immunsuppressive drugs such as cyclosporine, also results in an increase of PNPIII, which is normally secreted via the kidneys. 28 On the other hand, sepsis and MAHA, which affect the renal and hepatic clearance function also led to high serum levels of PNPIII in our trial.
The controversy of the data presented by different authors might on the on the hand be due to small numbers of patients included in the studies. Therefore, we conducted a large trial with more than 300 stem cell recipients included over several years. On the other hand the incidence of VOD after allogeneic HSCT differs a lot between the different studies. Most of the authors did not use the strict clinical criteria according to Jones et al. 2 This is why many of their patients actually did not meet all VOD criteria but were identified as VOD patients. Correspondingly the PNPIII levels were rather elevated in other TRC with hyperbilirubinemia than in VOD. According to a big retrospective trial of our group 15 and data from groups using the criteria according to Jones et al 2 we again could prove a low incidence of VOD with a very high mortality.
Conclusion
PC levels decrease during the development of VOD after HSCT. PNPIII plays a pivotal role in fibrous alterations in hepatic TRC. However, we conclude from this first large prospective study that PC plasma levels and PNPIII serum levels are only of limited help in the differential diagnosis of VOD.
